Song MJ, et al. - Researchers analyzed retrospectively obtained data of patients having small cell lung cancer (SCLC) with idiopathic pulmonary fibrosis (IPF) (SCLC-IPF) from two tertiary care university hospitals in South Korea, to determine survival outcomes and therapy-associated complications by GAP (gender, age, and physiology) stage. The advanced GAP stage group demonstrated inferior survival outcome and higher incidence of treatment-related pulmonary toxicities. Treatment-related acute exacerbation of IPF was only predicted by advanced GAP stage. Therefore, clinicians are recommended to take into account GAP stage, which indicates the severity of IPF, during treatment of SCLC-IPF.